Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.1%

30 terminated/withdrawn out of 271 trials

Success Rate

78.9%

-7.6% vs industry average

Late-Stage Pipeline

14%

37 trials in Phase 3/4

Results Transparency

21%

23 of 112 completed trials have results

Key Signals

39 recruiting23 with results22 terminated8 withdrawn

Enrollment Performance

Analytics

Phase 2

79(35.7%)

Phase 1

73(33.0%)

Phase 3

37(16.7%)

N/A

32(14.5%)

221Total

Phase 2(79)

Phase 1(73)

Phase 3(37)

N/A(32)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (271)

Showing 20 of 271 trials

NCT06380816Phase 1Recruiting

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Role: lead

NCT01398085Phase 2Active Not Recruiting

IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients

Role: collaborator

NCT02417662Not ApplicableActive Not Recruiting

Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer

Role: collaborator

NCT05848765Phase 2Recruiting

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Role: collaborator

NCT04307576Phase 3Recruiting

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Role: collaborator

NCT01888601Active Not Recruiting

TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)

Role: collaborator

NCT02664935Phase 2Completed

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Role: collaborator

NCT06447064Recruiting

Cancer Loyalty Card Study 2 (CLOCS-2)

Role: collaborator

NCT01679119Phase 2Completed

Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy

Role: collaborator

NCT07095517Phase 1Recruiting

Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

Role: collaborator

NCT07440290Phase 2Not Yet Recruiting

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

Role: lead

NCT07432932Recruiting

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

Role: collaborator

NCT05991388Phase 2Recruiting

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Role: collaborator

NCT04065269Phase 2Active Not Recruiting

ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

Role: collaborator

NCT05082259Phase 1Recruiting

ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab

Role: collaborator

NCT07391215Phase 1Recruiting

5G-PEARL: Paxalisib in Malignant Brain Tumours

Role: collaborator

NCT01737242Active Not Recruiting

UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies

Role: collaborator

NCT04648033Phase 1Completed

Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC

Role: collaborator

NCT07172958Phase 1Recruiting

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

Role: collaborator

NCT06630260Phase 1Recruiting

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Role: collaborator